Paul Rennert
@pdrworld.bsky.social
Biotech exec, pro drug developer. Amateur everything else: COOKING, ferments, preserving, charcuterie, fishing, gardening, weightlifting, BIRDER, photography, physics, literature, writer, history, DAD
birders---> maybe a good winter coming for northern finches and friends finchnetwork.org/winter-finch... #birders #birding #massbird
Winter Finch Forecast 2025-2026 - FINCH RESEARCH NETWORK
By Tyler Hoar Featured Post Photo: ©David Turgeon GENERAL FORECAST It looks to be a flight year for many species in Eastern Canada. With mostly very poor crops in the boreal forest from central Quebec...
finchnetwork.org
lovely writeup at BBC #Seurat bbc.com/culture/arti...
'As urgent and relevant today as it ever was': The radical manifesto hidden in Georges Seurat's 1884 masterpiece
Georges Seurat's once-mocked painting Bathers at Asnières is both an "exquisite distillation of the very essence of summer" and "a modern wonder in the art of seeing".
bbc.com
A very interesting bispecific ADC highlighted today by @JacobPlieth on X - oncologypipeline.com/apexonco/bri... while this discussion is focused on lung cancer, the first approval for iza-bren likely in nasopharyngeal carcinoma $BMY #SystImmune
Bristol's third pivotal iza-bren study
oncologypipeline.com
odd dynamic between clean energy needs and protecting ocean/avian ecosystems hard to choose a side? yep... chng.it/ThgpyJY2Pw
This campaign needs you now
Ban the over-use of single use plastics.
chng.it
Esobiotec's in vivo CAR-T data out in Lancet, n=4, multiple myeloma. These are the data that drove the $AZN acquisition, showing that the in vivo CAR-T results were equal to the ex vivo CAR-T results from Pregene w the same BCMA-CAR www.thelancet.com/journals/lan...
In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma
Chimeric antigen receptor (CAR) T-cell therapy has shown impressive efficacy in treating relapsed or refractory multiple myeloma. Nonetheless, its availability is substantially restricted by complex m...
thelancet.com
Concentra goes shopping again, adds CARGO to its market basket finance.yahoo.com/news/cargo-t... Cargo, IGM, Elevation Oncology, Kronos Bio, Allakos
HER3 activation and overexpression in cancers makes this antigen an attractive target for antibody therapeutics ---> a rapidly expanding drug development landscape has emerged sugarconebiotech.com/insights
In the inflammatory #fibrosis space, $PLRX stopped development of bexotegrast avb6/avb1 inhibitor for the treatment of IPF "due to worsening of IPF and acute IPF exacerbation, respiratory-related hospitalization, and/or all-cause mortality" (27 June 2025). Yikes.
tgif. goosebumps at this Wharf Rat, starts @ 10:28 www.youtube.com/watch?v=I1FV... the wheel is nice too, but man... 'i got up and wandered'
15. The Wheel -} Wharf Rat - Grateful Dead - 5/7/77 Boston Garden, Boston, MA - U31DoD 2012 Edition
YouTube video by NuttyRiv3r
youtube.com
quick series on emerging #cancer targets w updates post #ASCO25 from the biopharma/venture capital consultancy experts - sugarconebiotech.com #biotech #bioblue www.sugarconebiotech.com/insights/goo...
Good things come in 3s — SugarCone Biotech
DLL3, B7H3 and Her3 are compelling tumor antigens to target with cancer therapeutics. They have interesting patterns of expression in different cancer indications; thus, diverse therapies for attackin...
sugarconebiotech.com
A quick note of thanks to Esobiotec's management and Board of Directors as the AstraZeneca acquisition is now completed. Our job is done with this happy exit, and so the current Board, myself included, disperses. Its a bittersweet moment for me. #biotech #biosky www.astrazeneca.com/media-centre...
Acquisition of EsoBiotec completed
astrazeneca.com
ln early March I talked about the bispecific antibody landscape in IAI, specifically for atopic dermatitis and asthma. This remains a red hot area #biosky #biotech ... and we've added analysts to keep up the pace. See sugarconebiotech.com/insights/nov...
Novel bispecific antibodies – Part 2 – immunology, asthma and atopic dermatitis — SugarCone Biotech
In 1986 - nearly 40 years ago - the first antibody therapy was FDA-approved: muromonab-CD3 (Orthoclone OKT3®), a murine monoclonal antibody targeting human CD3 expressed on T cells. This therapy was u...
sugarconebiotech.com
Here we look at the state of In Vivo CAR T cell technology and companies, post Astra Zeneca's billion dollar Esobiotec acquisition and amid biotech's financing woes: www.sugarconebiotech.com/insights
Here we look at the state of In Vivo CAR T cell technology and companies, post Astra Zeneca's billion dollar Esobiotec acquisition and amid biotech's financing woes: www.sugarconebiotech.com/insights
Bye-Bei TIGIT - a lesson in the dangers of mediocre science butting up against the challenges of complex ligand/receptor interactions, FcReceptor biology, and cancer resistance mechanisms Beigene news via #ApexOnco www.oncologypipeline.com/apexonco/bei...
BeiGene bows out of TIGIT
AstraZeneca and GSK/iTeos's odysseys get a little lonelier still.
oncologypipeline.com
haven't listened to this '77 very much, it's blistering www.youtube.com/watch?v=wPgE...
Grateful Dead - Memorial Coliseum (Tuscaloosa, AL) 05/17/1977 (Complete Show)
YouTube video by Jack Straw From Wichita
youtube.com
omg it worked! #bispecifics #oncology #Tcells www.sugarconebiotech.com/insights/ale... cc www.aletabio.com
Aleta’s Novel T Cell Engagers — SugarCone Biotech
Aleta Bio recently announced that their scientists have created, characterized and validated novel classes of Immune Cell Engager therapeutics including T Cell Engagers (TCE) and CAR T Cell Engagers (...
sugarconebiotech.com
T CELL ENGAGER PROTEINS WITH BUILT IN COSTIMULATORY DOMAINS THAT TURN TUMOR CELLS INTO IMMUNE CELL MIMICS AND TRIGGER IMMUNE SYNAPSE SIGNALING ... www.aletabio.com/blog-1-1/ale... @BioAleta
Aleta’s Novel T Cell Engagers — Aleta Biotherapeutics
By Paul Rennert Aleta’s CSO and Co-Founder Paul Rennert talks about the company’s recent announcement that their scientists created, characterized, and validated novel classes of Immune Cell Engager...
aletabio.com
Our most potent T cell bispecifics leverage natural T cell immunology to kill cancer cells ... www.sugarconebiotech.com/insights/ale... proprietary technology that works just as well with CAR T engager proteins #aletabio #bispecifics #CARTcells
Aleta’s Novel T Cell Engagers — SugarCone Biotech
Aleta Bio recently announced that their scientists have created, characterized and validated novel classes of Immune Cell Engager therapeutics including T Cell Engagers (TCE) and CAR T Cell Engagers (...
sugarconebiotech.com
from last year, a blockbuster- The EBMT Handbook. Hematopoietic Cell Transplantation and Cellular Therapies" bit.ly/41n3IKb
The EBMT Handbook
This Open Access 8th ed. of the EBMT book addresses the latest developments and innovations in hematopoietic stem cell transplantation and cellular therapy
bit.ly
and we provide some broader #biotech #bioblue context www.sugarconebiotech.com/insights/pd1...
PD1 x VEGF bispecific landscape: examining Hope versus Hype. — SugarCone Biotech
There were waves of interest in this therapeutic space at ASCO in June 2024 and around the JP Morgan healthcare conference in January 2025. Here we take a look at the hope and the hype behind the PD1/...
sugarconebiotech.com
Paul Rennert@pdrworld.bsky.social · last yr.the ivonescimab clinical data have published in @thelancet.bsky.social www.thelancet.com/journals/lan... and they added some great commentary
the ivonescimab clinical data have published in @thelancet.bsky.social www.thelancet.com/journals/lan... and they added some great commentary
maybe $LEGN can test the thesis that there is only bad news for #biotech stocks ... they think 10,000 patients will receive CARVYKTI in 2025 ... looking at $2B in sales for this year
